Treatment of COPD: moving beyond the lungs

Current Opinion in Pharmacology
Maria Gabriella MateraMario Cazzola

Abstract

We still do not know whether the successful treatment of the comorbid diseases associated with COPD, mainly cardiovascular disease, also positively influences the course of the lung disease because so far there are few definite data documenting that treatment of COPD comorbidities will reduce morbidity and mortality rates in these patients. Observational studies suggest that COPD patients treated with statins, angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers, and β-adrenoceptor blockers may have improved survival and reduced hospitalisation from exacerbations. Progress in basic and translational research has led to a better understanding of pharmacological mechanisms that may explain the effects of these drugs on COPD and some small clinical trial activity is beginning to generate promising results.

References

Dec 28, 1999·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·M SuzukiY Ouchi
Feb 20, 2003·European Heart Journal·P O BonettiA Lerman
Jul 2, 2003·Thorax·R Forth, H Montgomery
Aug 1, 2006·Thorax·E HothersallN C Thomson
Aug 21, 2007·Pulmonary Pharmacology & Therapeutics·Nicola A HananiaRichard A Bond
Sep 28, 2007·Trends in Pharmacological Sciences·Mario CazzolaClive Page
Oct 3, 2007·Expert Opinion on Therapeutic Targets·Mario CazzolaMaria G Matera
Oct 26, 2007·The European Respiratory Journal·R M Wösten-van AsperenA P Bos
Dec 22, 2007·American Journal of Respiratory Cell and Molecular Biology·Long P NguyenRichard A Bond
Mar 4, 2008·American Journal of Respiratory and Critical Care Medicine·Don D SinUNKNOWN ABC (Advair, Biomarkers in COPD) Investigators
Sep 18, 2008·American Journal of Respiratory and Critical Care Medicine·Mario Cazzola, Maria Gabriella Matera
May 2, 2009·The European Respiratory Journal·P J Barnes, B R Celli
May 9, 2009·Respiratory Medicine·Julie LeeMorten Dahl
Jun 6, 2009·Respiratory Research·Eric M MortensenAntonio Anzueto
Jul 15, 2009·BMC Pulmonary Medicine·Claudia C DoblerGuy B Marks
Dec 3, 2009·Genome Medicine·Alice M WoodRobert A Stockley
Jan 26, 2010·Pulmonary Pharmacology & Therapeutics·Fabiano Di MarcoStefano Centanni
Feb 6, 2010·Respiration; International Review of Thoracic Diseases·Mario CazzolaGianluca Biscione
Apr 20, 2010·Current Opinion in Pharmacology·Burton F DickeyRichard A Bond
Aug 6, 2010·Thorax·Peter M A CalverleyUNKNOWN TORCH Investigators
Aug 17, 2010·American Journal of Respiratory and Critical Care Medicine·Joanne L WrightAndrew M Churg
Oct 20, 2010·European Respiratory Review : an Official Journal of the European Respiratory Society·R P YoungT E Eaton
Dec 29, 2010·Pulmonary Pharmacology & Therapeutics·Tobias RaupachStefan Andreas
Jan 7, 2011·Chest·Yvonne Nussbaumer-Ochsner, Klaus F Rabe
Feb 1, 2011·American Journal of Respiratory Cell and Molecular Biology·Mario CazzolaMaria Gabriella Matera
May 12, 2011·BMJ : British Medical Journal·Philip M ShortBrian J Lipworth
May 12, 2011·BMJ : British Medical Journal·Shamsah Kazani, Elliot Israel
Jun 24, 2011·Respiratory Medicine·Mark T DransfieldFernando J Martinez
Jul 7, 2011·Pulmonary Pharmacology & Therapeutics·Konstantinos BartziokasKonstantinos I Gourgoulianis
Sep 13, 2011·Lancet·Klaus F Rabe, Jadwiga A Wedzicha
Feb 18, 2012·Expert Opinion on Emerging Drugs·Maria Gabriella MateraMario Cazzola

❮ Previous
Next ❯

Citations

Oct 30, 2013·European Journal of Clinical Investigation·Sara RoversiLeonardo M Fabbri
Feb 20, 2016·Expert Opinion on Pharmacotherapy·Mario CazzolaMaria Gabriella Matera
Oct 5, 2012·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Diana SilvaAndré Moreira
Jul 26, 2015·The Lancet. Respiratory Medicine·Mario CazzolaMaria Gabriella Matera
Oct 31, 2017·Expert Review of Respiratory Medicine·Mario CazzolaMaria Gabriella Matera
Oct 9, 2014·Immunological Investigations·Mark Reza LaftaviOleh Pankewycz
Dec 13, 2016·Drugs -- Real World Outcomes·Mayank AjmeraUsha Sambamoorthi
Feb 10, 2021·Expert Review of Clinical Pharmacology·Maria Gabriella MateraMario Cazzola

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.